Clinician Link.AI ™️’s Post

🌟🔍 Dive deep with Dr. KOROBELNIK at European Society of Retina Specialists (EURETINA) as he unveils insightful findings from his subgroup analysis of the Pulsar study. Throughout #Euretina2024, Dr. Korobelnik has shared pivotal data, with a particular focus on how various factors like retinal thickness, disease duration, and patient demographics impact treatment outcomes with EYLEA HD® (aflibercept) Injection HCP eight milligram. 📊 His analysis reveals that these factors surprisingly do not affect the treatment intervals, with 40-50% of patients achieving extended dosing intervals. This highlights the robust effectiveness of the treatment across diverse patient groups. 💡 Join us as Dr. Korobelnik continues to shed light on the nuances of retinal treatments and their implications on clinical practice. Stay tuned for more groundbreaking updates from the front lines of ophthalmology research! #Euretina #Ophthalmology #EyeCare #RetinaSpecialist #MedicalInnovation #VisionHealth #EyeHealth #DigitalHealth #Retina #Ophthalmology #ClinicianLinkLive  Bayer Bayer | Ophthalmology

Unlock Mondays with an exciting publication! Are you curious about the prognosis and influencing factors of anti-VEGF therapy in patients with retinal vein occlusion (RVO) who also have carotid artery disease? Check out the publication 'Prognosis and factors related to anti-VEGF therapy in patients with retinal vein occlusion and concomitant carotid artery disease.' This study evaluates treatment effectiveness and identifies key risk factors affecting visual prognosis in these patients. What implications do these findings have for optimizing treatment strategies? Stay informed with the latest insights in ophthalmology. Discover it: https://lnkd.in/dUV2TGZZ #Ophthalmology #Publication #RetinalVeinOcclusion #AntiVEGF #CarotidArteryDisease

👁️🔬 Dr. David Eichenbaum shares groundbreaking findings from his study on aflibercept high dose (EYLEA® HD (aflibercept) Injection HCP 8mg) in treating wet AMD. As the first real-world data set, the study reveals that while a significant portion of patients responded positively, extending treatment intervals, a segment still required more frequent care. This pivotal research highlights the importance of personalized medicine in ophthalmology, as responses vary widely among patients. Discover more about how these insights are shaping future treatment protocols. #ASRS2024 #Ophthalmology #MedicalLeadership #VisionaryInOphthalmology #MedicalInnovation #RetinaSpecialists #EyeCareInnovation #VisionScience #MedTech #HealthcareTrends #ClinicalResearch ASRS – American Society of Retina Specialists Bayer Bayer | Ophthalmology Saghar Bagheri MD PhD

🌟 Excited to Share Our Latest Publication! 🌟 Thrilled to announce the publication of our big data study on intraocular pressure and gonioscopic findings in primary angle-closure disease in India. This research emphasizes the critical role of gonioscopy and the importance of measuring post-dilated intraocular pressure (IOP) in routine practice to identify at-risk cases early. It was indeed a tough journey, with many rejections along the way, but perseverance paid off! A huge thank you to my esteemed co-authors, Anthony Vipin Das and Sirisha Senthil, for their unwavering collaboration and expertise. This study wouldn’t have been possible without our combined efforts. Together, we aim to contribute to better outcomes in glaucoma care. For those interested in the details, the publication is now available in the latest issue of the International Journal of Ophthalmology. Let’s continue pushing the boundaries of ophthalmic research! 👁️🔬 #Ophthalmology #GlaucomaResearch #BigData #AngleClosure #Gonioscopy #PostDilatedIOP

🎥 Delve into the science of dosing with Dr. Peter Kaiser as he discusses the enhanced durability of Bayer | Ophthalmology 8 mg aflibercept. Learn how increasing the molar dose can extend the drug's half-life, offering tailored treatment intervals based on individual patient needs. Dr. Kaiser sheds light on the practical application of these findings, emphasizing the importance of a patient-centric approach in optimizing treatment outcomes. Explore the nuances of treat-and-extend paradigms with high-dose Eylea, and discover how personalized care is revolutionizing patient experiences in ophthalmology.  #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress Simrat Sodhi

#JOJ Ophthalmology #Impair Color Vision by Impair Cerebellum Pathway: Comparison with Parkinson’s Disease #Abstract: From the retinal receptors to the visual cortex can originate any visive abnormality, anywhere in the visual pathway. Previously, we showed as Parkinson’s Disease affects dopaminergic substantia nigra neurons within the brain system, and the decline in color vision may be predicted by the level of retinal dopamine deficiency. #Impair Color Vision #Parkinson’s Disease #Retinal Receptors #Granule Cells #https://lnkd.in/e_J2NK4j #https://lnkd.in/eMX8BUPz

#Autoimmune #retinopathy is a rare, mysterious, and devastating disorder. In our latest #publication in the Canadian Journal of Ophthalmology, we describe a series of cases with autoimmune retinopathy and concurrent systemic autoimmune disease, highlighting diagnostic and therapeutic challenges and the importance of #multimodal_imaging in such cases. Pre-proof version available here: https://lnkd.in/d28i3SFs

🎥 Join Dr. Peter Kaiser as he delves into the significant advancements in ophthalmic treatment with the introduction of Bayer | Ophthalmology 8 mg aflibercept. Discover how this higher dosage is making strides in patient care, allowing for extended treatment intervals and improved outcomes, especially for those with challenging cases. Dr. Kaiser shares his experiences and the promising results observed in two distinct patient groups, showcasing the drug's versatility and effectiveness. Tune in to gain valuable insights into this groundbreaking development in ophthalmology! #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress

Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication, "Vascular Endothelial Growth Factor (VEGF) C and D Signaling Pathways as Potential Targets for the Treatment of neovascular (wet) AMD," underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with standard-of-care anti-VEGF-A therapies. Read press release here: https://lnkd.in/ez62P5NG We want to thank the authors: Ian Leitch Mike Gerometta David Eichenbaum @Robert Finger Nathan Steinle Megan Baldwin Access the full publication: https://lnkd.in/eu2-_Bdt #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

🎥 Discover the future of personalized treatment with Dr. Peter Kaiser (Cleveland Clinic Lerner Research Institute) at COPHy Congress, as he discusses the integration of Home OCT and machine learning in patient care. Learn how this innovative approach allows for as-needed treatments, providing medication only when necessary, based on precise leakage detection. This method not only optimizes patient outcomes but also aligns with the patient's individual needs, ensuring they receive treatment at the exact right moment. Join Dr. Kaiser as he explores how technology is transforming the way we approach and deliver care in ophthalmology. #COPHY2024 #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy